论文部分内容阅读
用ＥＬＩＳＡ及ＡＰＡＡＰ法分别检测了３９例乙型肝炎病毒（ＨＢＶ）感染者、１５例有ＨＢＶ感染的肝癌患者及２０例正常人的血清可溶性白细胞介素－２受体（ＳＩＬ－２Ｒ）和外周血Ｔ淋巴细胞亚群。结果显示，肝癌及ＨＢＶ感染者的血清ＳＩＬ－２Ｒ均明显高于正常人（Ｐ＜０．０１），肝癌患者的ＳＩＬ－２Ｒ明显高于ＨＢＶ感染者（Ｐ＜０．０１）。肝癌患者及ＨＢＶ感染者的ＣＤ３、ＣＤ４、ＣＤ８、ＣＤ４／ＣＤ８与对照相比均有显著差异（Ｐ＜０．０５），而肝癌与ＨＢＶ感染者相比无显著差异（Ｐ＞０．０５）。提示ＨＢＶ感染者及肝癌患者均存在细胞免疫功能紊乱，尤以肝癌患者明显；ＣＤ４、ＣＤ４／ＣＤ８下降可能是引发肝癌的基础；血清ＳＩＬ－２Ｒ显著升高可能是肝癌发生的重要原因，也是ＨＢＶ感染者可能发生癌变的重要指标。
The serum soluble interleukin-2 receptor (SIL-2R) and peripheral serum of 39 patients with hepatitis B virus (HBV) infection, 15 patients with liver cancer with HBV infection, and 20 normal individuals were detected by ELISA and APAAP method. Blood T lymphocyte subsets. The results showed that the serum levels of SIL-2R in patients with hepatocellular carcinoma and HBV infection were significantly higher than those in normal controls (P<0.01). The SIL-2R in patients with hepatocellular carcinoma was significantly higher than those in patients with HBV infection (P<0.01). The difference of CD3, CD4, CD8, CD4/CD8 between patients with hepatocellular carcinoma and HBV infection was significant (P<0.05), but there was no significant difference between liver cancer and HBV infection (P>0.05). . It is suggested that there are cell immune disorders in patients with HBV infection and liver cancer, especially in patients with liver cancer; the decline of CD4 and CD4/CD8 may be the basis for triggering liver cancer; a significant increase in serum SIL-2R may be an important cause of liver cancer, and also HBV Infected persons may have important indicators of canceration.